Sign In
Buy HOTH
$1.36
+0 (+0%)
At Close: Jun 03, 2026
Why Is Hoth Therapeutics (HOTH) Stock Moving Today?
11:22am, Wednesday, 24'th Jul 2024
Hoth Therapeutics (NASDAQ: HOTH ) stock is on the move Wednesday after the clinical-stage biopharmaceutical company announced a new partnership with LTS Therapy Systems. This partnership has the two c
Hoth Therapeutics Expands Clinical Trial for Cancer Patients
08:31am, Tuesday, 16'th Jul 2024
Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health NEW YORK , July 16, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a patient-focused biopharm
Nvidia BioNeMo generative AI platform will be used to accelerate the training of models on proprietary data NEW YORK , June 10, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient f
Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024
08:00am, Wednesday, 01'st May 2024
NEW YORK , May 1, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the EF H
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
02:00pm, Wednesday, 27'th Mar 2024
NEW YORK , March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
08:27am, Wednesday, 27'th Mar 2024
Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer Program NEW YORK , March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
06:41am, Wednesday, 20'th Mar 2024
Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
08:21am, Tuesday, 19'th Mar 2024
HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease. NEW YORK , March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, In
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
08:38am, Thursday, 29'th Feb 2024
NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced that it will continue its work with Venable, LLP to deve
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
08:11am, Monday, 26'th Feb 2024
Hoth's HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derived Cancers NEW YORK , Feb. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (N
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
11:45am, Tuesday, 13'th Feb 2024
NEW YORK , Feb. 13, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the BIO
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
08:20am, Thursday, 18'th Jan 2024
Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics NEW YORK , Jan. 18, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focuse
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies
08:33am, Tuesday, 05'th Dec 2023
NEW YORK , Dec. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has completed the manufacturing of its drug substance H
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT
08:37am, Tuesday, 14'th Nov 2023
Hoth intends to continue development under Orphan Drug Designation NEW YORK , Nov. 14, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today t
Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023
08:00am, Friday, 10'th Nov 2023
NobleCon is the preeminent showcase of small and microcap companies NEW YORK , Nov. 10, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that
